Raised D-dimer among Admitted COVID-19 Patients in a Tertiary Care Centre: A Descriptive Cross-sectional Study

Dipesh Karki,1 Roshani Gurung,2 Prasanna Nepali,3 Hari Prasad Kaphle,4 Bhabuk Subedi,5 Sundar Adhikari6

1Department of Medicine, Fishtail Hospital and Research Center Private Limited, Pokhara, Kaski, Nepal, 2Pharmacy Programme, Gandaki University, Pokhara, Kaski, Nepal, 3Fishtail Hospital and Research Center Private Limited, Pokhara, Kaski, Nepal, 4School of Health and Allied Sciences, Pokhara University, Pokhara, Kaski, Nepal, 5Department of Intensive Care Unit, Fishtail Hospital and Research Center Private Limited, Pokhara, Kaski, Nepal, 6Department of Pharmacy, Fishtail Hospital and Research Center Private Limited, Pokhara, Kaski, Nepal.

ABSTRACT

Introduction: Patients with COVID-19 are characterised by abnormal levels of inflammatory biomarkers. Elevated D-dimer in COVID-19 patients is associated with increased mortality. This study aimed to find out the prevalence of raised D-dimer among COVID-19 patients in a tertiary care centre.

Methods: This descriptive cross-sectional study was conducted in COVID-19 unit of a tertiary care centre from 23 January 2021 to 19 June 2021. The ethical approval was taken from the Institutional Review Committee (Reference number: 077/078/159). D-dimer values and demographic data of the hospital-admitted COVID-19 patients were recorded. Convenience sampling technique was used. Point estimate and 95% Confidence Interval were calculated.

Results: Out of 180 patients with COVID-19 admitted in the hospital, the D-dimer levels were raised in 85 (47.22%) (39.93-54.51, 95% Confidence Interval) patients.

Conclusions: The prevalence of raised D-dimer among admitted COVID-19 patients was found to be lower when compared to other studies conducted in similar settings.

Keywords: COVID-19; D-dimer; Nepal; prevalence.

INTRODUCTION

Patients with Coronavirus Disease-2019 (COVID-19) are characterised by abnormal levels of inflammatory biomarkers such as C-reactive protein (CRP), ferritin, fibrinogen and especially elevated level of D-dimer which indicates need for critical care and may lead to death.1

D-dimer is a fibrin degradation product (fibrinolysis) that circulates in blood plasma at low blood concentration where value less than 0.5 μg/ml is usually considered normal.2 D-dimer value is used for the investigation of venous thromboembolism, pulmonary embolism and now list has been added to the investigation of COVID-19 patients because the level of D-dimer rises with increased severity of community acquired pneumonia.3 It was first reported by physician in Wuhan, China, found to be independently associated with mortality having D-dimer > 1 μg/ml.4,5 This study aimed to find out the prevalence of raised D-dimers among COVID-19 patients in a tertiary care centre.

METHODS

This descriptive cross-sectional study was conducted in COVID-19 unit of a tertiary care centre from 23 January 2021 to 19 June 2021 at the peak time of COVID-19 second wave in Nepal. The Institutional Review Committee of Fishtail Hospital and Research Centre Private Limited, Pokhara, Nepal, provided the ethical approval for the study (Reference number: 077/078/159). Hospitalised patients with confirmed...
COVID-19 by reverse transcription polymerase chain reaction (RT-PCR) using nasopharyngeal swab were included in this study. Patients with the diagnosis of cancer, hematologic malignancy, acute coronary syndrome, presence of other infections, chronic liver disease, trauma or surgery within 30 days, patients with prior use of anticoagulants, pregnancy, patients without prior recorded D-dimer upon admission and cases without recorded outcomes were excluded from the study. Convenience sampling was done, and sample size was calculated by using the following formula:

\[ n = \frac{Z^2 \times p \times q}{e^2} \]

Where,
- \( n \) = minimum required sample size
- \( Z = 1.96 \) at 95% of Confidence Interval (CI)
- \( p = \) prevalence taken as 50% for maximum sample size calculation
- \( q = 1 - p \)
- \( e = \) margin of error, 8%

The calculated sample size was 150. Taking a 20% non-response rate, the sample size was 180.

The reference level for raised D-dimer level is \( \geq 0.5 \) mg/dL. The demographic data of the respondents were taken as gender and age. Age was categorised into three classes as the age group from 20 to 39, 40 to 59, and 60 or above. For the assessment of D-dimer, blood samples were collected within 24 hours of admission and sent to the laboratory department of the hospital. Analysis was done on Ichroma (manufactured in South Korea) by the Fluorescence Immunoassay (FIA) method. All measurements were done in the laboratories within 2 hours of sample collection.

For data entry and analysis, Microsoft Excel and IBM SPSS Statistics 20.0 was used. Point estimate and 95% CI were calculated.

## RESULTS

Out of 180 patients with COVID-19 admitted in the hospital, the D-dimer levels were raised in 85 (47.22%) (39.93-54.51, 95% CI) patients. Among the patients with elevated D-dimer, 31 (36.47%) patients expired (Table 1).

### Table 1. Treatment outcome in COVID-19 patients with elevated D-dimer (n= 85).

| Treatment outcome                  | n (%)     |
|------------------------------------|-----------|
| Discharge on patient request/Discharged | 54 (63.53) |
| Expired                            | 31 (36.47) |

Among the admitted patients with COVID-19, the raised d-dimer levels were found in 45 (52.94%) female patients (Figure 1).

**DISCUSSION**

In this study, the prevalence of raised D-dimer was found to be 47.22%. Among them 36.47% of the patients died. The ongoing pandemic of COVID-19 poses several challenges to clinicians. To control this situation, many allopathic medicines have been used in practice but no conclusive treatment has arrived. On another side, it is found to have an advantageous effect of different medicinal plants which are traditionally used as antiviral, and anti-inflammatory properties and possesses phytochemicals like alkaloids, glycosides, phenol, flavonoid etc. on COVID-19 treatment. Due to rapid disease progression, causing severe and fatal complications, it is necessary to screen COVID-19 patients for biomarkers, categorization of patients, their clinical management, and prevention of serious complications. Biomarkers commonly evaluated to access severity of COVID-19 diseases are D-dimer, serum ferritin, C-reactive protein (CRP), Interleukin-6, Lactate dehydrogenase (LDH), and CT Severity score derived from a patient’s CT imaging.

D-dimers are one of the fragments produced when...
plasmin cleaves fibrin to break down clot. It is the smallest protein fragment identified in blood when a blood clot is degraded (fibrinolysis). In previous studies, it is found that higher the D-dimer level, the patient is more severe with higher mortality rate which might be associated with the severity of inflammation prior coagulopathy/thrombosis that lead to poor outcomes, even death. Similar case has also been seen in our study, the mortality rate was higher with the patients having D-dimer value ≥0.5 μg/ml. Most of the patients with mortality were female (52.94%) where mortality rate for male was (47.06%) and age group 40-59 years (43.53%) followed by 60 and above (41.18%). This study was supported by the previous studies. 

A published study reported that COVID-19 patient admitted to the intensive care units has elevated level of D-dimer value. Also, study conducted in 279 COVID-19 patients in three hospitals in Hubei Province, China shows the strong relationship between D-dimer level and the progression of COVID-19.

This was a single-centred study. In the future, it is necessary to do such a study with a larger sample in multiple centres. Association between the parameters could not be established. Furthermore, other biomarkers can also be compared for the severity assessment and outcome of a patient’s treatment with COVID-19.

CONCLUSIONS

The prevalence of raised D-dimer among admitted COVID-19 patients was found to be lower when compared to other studies conducted in similar settings. In this study, the mortality rate of COVID-19 patients with raised D-dimer was over one third. However, it is necessary to do further research to clarify risk of severity in COVID-19 patients with elevated D-dimers which are the result of thrombotic burden or tendency, inflammation, or a combination therein.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the Department of Pharmacy, Department of Medicine, Department of Laboratory, Fishtail Hospital and Research Center Private Limited, Pokhara, Nepal.

Conflict of Interest: None.

REFERENCES

1. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021 Apr;76(4):412-20. [PubMed] Full Text | DOI

2. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021 Aug 26;16(8):e0256744. [PubMed] Full Text | DOI

3. Berger JS, Kunichoff D, Adhikari S, Parajuli K. Evaluation of the prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2539-2547. [PubMed] Full Text | DOI

4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. [PubMed] Full Text | DOI

5. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245-9. [PubMed] Full Text | DOI

6. Karki D, KC S, Gurung R, Adhikari S. Association of HRCT severity score, pre-existing comorbidities, and ABO blood group with treatment outcomes of COVID-19 patients admitted in a hospital of Western Nepal. Asian Journal of Medical Sciences. 2022 Apr 1;13(4):1-6. [Full Text | DOI]

7. Gurung R, Arawal R, Thapa Y, Khanal S, Gautam S. Preliminary phytochemical screening, in-vitro antioxidant and antibacterial activity of Begonia pecta. World J Pharm Sci. 2019 Sep;8(10):1241-57. [Full Text | DOI]

8. Gurung RO. Preliminary phytochemical screening, total phenol and flavonoid content of Mimosa rubicaulis and Reinwardtia indica. International Journal of Pharmacy and Pharmaceutical Sciences. 2020 Jan;12(1):54-8. [Full Text | DOI]

9. Gurung R, Adhikari S, Parajuli K. Evaluation of the antibacterial and antioxidant activity of Mimosa rubicaulis and Reinwardtia indica. Evid Based Complement Alternat Med. 2020 Nov 10;2020:3862642. [PubMed] Full Text | DOI

10. Gurung R, Koirala N, Gurung P, Tamang BM, Chettri S, Basnet B, et al. Reinwardtia indica: phytochemical screening and evaluation of wound healing activity of the extracts in experimental model rats. Cell Mol Biol (Noisy-le-grand). 2021 Jan 31;67(1):24-31. [PubMed] Full Text | DOI

11. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-99. [PubMed] Full Text | DOI

12. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020 Jun;95:304-7. [PubMed] Full Text | DOI

13. Wang L, Yang L, Bai L, Huang Z, Peng Y. Association between D-dimer level and chest CT severity score in patients with SARS-COV-2 pneumonia. Sci Rep. 2021 Jun 2;11(1):11636. [PubMed] Full Text | DOI
14. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020 Nov;195:219-25. [PubMed | Full Text | DOI]

15. Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol. 2020 Jul;190(1):e24-7. [PubMed | Full Text | DOI]